Deal News

IGM and ADC enter clinical trial partnership deal for lymphoma treatment

IGM Biosciences has signed a clinical trial partnership and supply agreement with ADC Therapeutics to analyse the combination of imvotamab and…

Erasca and Pfizer enter trial partnership for palbociclib

Erasca and Pfizer have entered a clinical trial partnership and supply agreement for palbociclib (Ibrance), an inhibitor of CDK4/6. Under the collaboration, the companies…

GSK and Tempus partner to boost clinical trial design

GSK has signed a three-year partnership agreement with Tempus to enhance clinical trial design, expedite subject enrolment and detect drug targets. Under the…

Lightship and Acclinate to boost trial access for underrepresented people

Lightship has entered a collaboration with Acclinate to boost access and engagement in clinical trials for populations which are underrepresented.…

TILT Biotherapeutics and MSD partner for lung cancer treatment trial

TILT Biotherapeutics and MSD (Merck) have entered a clinical trial collaboration and supply agreement for an oncolytic immunotherapy candidate, TILT-123, for non-small cell lung…

Pfizer and Strata expand clinical partnership for cancer trial

Pfizer and Strata Oncology have expanded their partnership for a clinical trial assessing various cancer therapies in new, biomarker-guided patient groups. Named Strata…

OncoResponse and Regeneron enter cancer therapy clinical supply agreement

OncoResponse has entered a clinical supply agreement with Regeneron for the latter’s Libtayo (cemiplimab), a PD-1 inhibitor. The deal will…

BMS, Disability Solutions launch programme to boost trial diversity

Bristol Myers Squibb (BMS) has entered a partnership with US-based non-profit organisation Disability Solutions for the Disability Diversity in Clinical Trials…

Worldwide Clinical Trials, Invitae partner to expedite rare disease trials

Worldwide Clinical Trials has entered a strategic collaboration with medical genetics company Invitae to expedite clinical trials for rare disease patients. Under…

Cybin completes purchase of anxiety disorder treatment study

Cybin has completed the previously announced acquisition of a Phase I N,N-dimethyltryptamine (DMT) study of anxiety disorder treatment from Entheon…